• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Reduced B cell antigenicity of Omicron lowers host serologic response

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Sep 28;111512.
doi: 10.1016/j.celrep.2022.111512. Online ahead of print.
Reduced B cell antigenicity of Omicron lowers host serologic response


Jérôme Tubiana[SUP] 1 [/SUP], Yufei Xiang[SUP] 2 [/SUP], Li Fan[SUP] 3 [/SUP], Haim J Wolfson[SUP] 4 [/SUP], Kong Chen[SUP] 5 [/SUP], Dina Schneidman-Duhovny[SUP] 6 [/SUP], Yi Shi[SUP] 7 [/SUP]



Affiliations

Abstract

The SARS-CoV-2 Omicron variant evades most neutralizing vaccine-induced antibodies and is associated with lower antibody titers upon breakthrough infections than previous variants. However, the mechanism remains unclear. Here, we find using a geometric deep-learning model that Omicron's extensively mutated receptor binding site (RBS) features reduced antigenicity compared with previous variants. Mice immunization experiments with different recombinant receptor binding domain (RBD) variants confirm that the serological response to Omicron is drastically attenuated and less potent. Analyses of serum cross-reactivity and competitive ELISA reveal a reduction in antibody response across both variable and conserved RBD epitopes. Computational modeling confirms that the RBS has a potential for further antigenicity reduction while retaining efficient receptor binding. Finally, we find a similar trend of antigenicity reduction over decades for hCoV229E, a common cold coronavirus. Thus, our study explains the reduced antibody titers associated with Omicron infection and reveals a possible trajectory of future viral evolution.

Keywords: CP: Immunology; CP: Microbiology; Omicron variant of concern; SARS-CoV-2; antigenicity; computational structural biology; deep learning; spike protein.
 
Back
Top Bottom